| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 27.2 | 34.0 |
| Gross profit | 17.1 | 21.9 |
| Profit before tax | -1.2 | 4.8 |
| Net income | -1.2 | 4.6 |
| EPS (diluted, $ a share) | $-0.01 | $0.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -20.0% |
|---|---|
| Gross margin | 62.9% |
| Operating margin | -5.8% |
10-Q filed with the SEC, NASDAQ: NAGE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Niagen Bioscience, Inc.: key numbers
- Share price
- $2.01Close, Nov 16
- Market cap
- $159M
- Shares outstanding
- 79.2MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Niagen Bioscience, Inc.
All →Niagen Bioscience Earnings Call: Key Takeaways
Niagen Bioscience is navigating a transitional 2026 investment year, focusing on new salt forms and pharmaceutical pipelines to offset current revenue declines and ingredient pricing pressure.
- Call
- Nov 4, 2026, 4:30 PM ET
Niagen Bioscience Financial Results
Niagen Bioscience reported Q3 2026 net sales of $27.2 million and a net loss of $1.2 million, while generating $2.6 million in operating cash flow. The company launched several new products including Niagen NanoCloud topical and an at-home injection kit, while expanding retail distribution through Walmart.com, GNC, and Sam's Club.
- Term
- Q3 2026
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform. We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”
Rob Fried, Chief Executive Officer